Lance Thibault

Biography

Mr. Lance Thibault joined Pieris Pharmaceuticals as Acting Chief Financial Officer in February 2017. Mr. Thibault, joins the Company from Danforth Advisors where he has served as a consulting chief financial officer since January 2014, providing operational, financial and strategic services at a number of public and private pharmaceutical and biotechnology companies. Mr. Thibault’s previous experience includes interim chief financial officer with Proteostasis Therapeutics, Inc. (NASDAQ: PTI) where he helped lead the company in its successful U.S. initial public offering in February 2016, as interim finance director for Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) bridging through the company’s 2014 reverse merger, and has provided specialized assistance to several companies, including, Dimension Therapeutics (NASDAQ: DMTX) and Basilea Pharmaceutica Ltd (SIX Swiss Exchange: BSLN), making advance preparations in the areas of financial reporting, operational activities, internal controls, systems and accounting functions. From 2002 to 2010, Mr. Thibault was Chief Financial Officer and Treasurer of deCODE genetics, Inc. (NASDAQ: DCGN), a biotechnology and genetics research Company, and prior to that time was a director with PricewaterhouseCoopers LLP’s transaction advisory services global capital markets group in London, England providing SEC reporting expertise to private foreign registrants executing primary and secondary debt and equity offerings in the U.S. Mr. Thibault is a CPA and received his B.S. in Accountancy from Bentley College.

Research Interest

financial reporting, operational activities, internal controls, systems and accounting functions